Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.

被引：18

作者：

Dummer, Reinhard

Schadendorf, Dirk

Ascierto, Paolo Antonio

Fernandez, Ana Maria Arance

Dutriaux, Caroline

Maio, Michele

Rutkowski, Piotr

Del Vecchio, Michele

Gutzmer, Ralf

Mandala, Mario

Thomas, Luc

Wasserman, Ernesto

Ford, James

Weill, Marine

Sirulnik, L. Andres

Jehl, Valentine

Bozon, Viviana

Long, Georgina V.

Flaherty, Keith

机构：

[1] Univ Zurich Hosp, Zurich, Switzerland

[2] Univ Hosp Essen, Essen, Germany

[3] Fdn Pascale, Ist Nazl Tumori, Naples, Italy

[4] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

[5] CHU Bordeaux, Hop St Andre, Bordeaux, France

[6] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy

[7] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[8] Inst Oncol, Warsaw, Poland

[9] Ist Nazl Tumori, Milan, Italy

[10] Hannover Med Sch, Hannover, Germany

[11] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy

[12] Univ Lyon 1, Ctr Hosp Lyon Sud, Pierre Benite, France

[13] Novartis Pharmaceut, Florham Pk, NJ USA

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Array BioPharma, Boulder, CO USA

[17] Melanoma Inst Australia, Sydney, NSW, Australia

[18] Univ Sydney, Sydney, NSW, Australia

[19] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_supll.9500

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

9500

引用

页数：2